CervoMed is a clinical-stage biotech developing neflamapimod, a single oral drug candidate targeting several age-related neurological diseases. Neflamapimod works by inhibiting p38α, an enzyme that drives neuroinflammation and synaptic dysfunction in the brain. The core hypothesis is that many neurodegenerative diseases pass through a phase of reversible synaptic dysfunction before causing permanent neuron death, and that blocking p38α can restore synaptic function and slow or reverse early cognitive and motor decline. CervoMed's lead indication is Dementia with Lewy Bodies (DLB), specifically "pure DLB" patients without co-occurring Alzheimer's pathology — roughly half of the estimated 700,000+ DLB patients in the US and EU. No approved disease-modifying therapies exist for DLB in either market. CervoMed also has neflamapimod in early-stage trials for nonfluent/agrammatic variant Primary Progressive Aphasia (a frontotemporal dementia subtype), recovery after ischemic stroke, and ALS. CervoMed has no revenue and funds operations through equity raises and grants, including a $21M grant from the National Institute on Aging covering much of its Phase 2b DLB trial costs. If neflamapimod is approved, CervoMed plans to commercialize it directly in North America and Europe, while potentially partnering for other regions. CervoMed would owe milestone payments of up to $117M and low- to mid-teens royalties on net sales to Vertex, which originally developed and licensed neflamapimod to CervoMed. CervoMed does not own manufacturing facilities and relies on contract manufacturers.